ACE2 and COVID-19: Histopathological examination of brain tissue in necropsied patients has also demonstrated neurological complications in a subset of COVID‐19 patients implicating non‐inflammatory neurovascular damage in clinical manifestations ranging from loss of olfaction/gustation to loss of involuntary control of breathing through medullary centres, with the virus hypothesized to spread to the brain from the upper respiratory tract via the transcribrial route, where angiotensin‐converting enzyme 2 (ACE2)‐expressing tissues enable viral internalization.15